These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 22067400)

  • 1. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
    Maas M; Beets-Tan RG; Lambregts DM; Lammering G; Nelemans PJ; Engelen SM; van Dam RM; Jansen RL; Sosef M; Leijtens JW; Hulsewé KW; Buijsen J; Beets GL
    J Clin Oncol; 2011 Dec; 29(35):4633-40. PubMed ID: 22067400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study.
    Li J; Liu H; Yin J; Liu S; Hu J; Du F; Yuan J; Lv B; Fan J; Leng S; Zhang X
    Oncotarget; 2015 Dec; 6(39):42354-61. PubMed ID: 26472284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 4. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
    Lambregts DM; Vandecaveye V; Barbaro B; Bakers FC; Lambrecht M; Maas M; Haustermans K; Valentini V; Beets GL; Beets-Tan RG
    Ann Surg Oncol; 2011 Aug; 18(8):2224-31. PubMed ID: 21347783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
    Ihn MH; Kang SB; Kim DW; Oh HK; Lee SY; Hong SM
    Dis Colon Rectum; 2014 Aug; 57(8):958-66. PubMed ID: 25003290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.
    Gérard JP; Chamorey E; Gourgou-Bourgade S; Benezery K; de Laroche G; Mahé MA; Boige V; Juzyna B
    Radiother Oncol; 2015 May; 115(2):246-52. PubMed ID: 25921382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
    Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
    Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
    Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
    Cercek A; Roxburgh CSD; Strombom P; Smith JJ; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Seier K; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Crane CH; Gollub MJ; Garcia-Aguilar J; Saltz LB; Weiser MR
    JAMA Oncol; 2018 Jun; 4(6):e180071. PubMed ID: 29566109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.
    Martens MH; Maas M; Heijnen LA; Lambregts DM; Leijtens JW; Stassen LP; Breukink SO; Hoff C; Belgers EJ; Melenhorst J; Jansen R; Buijsen J; Hoofwijk TG; Beets-Tan RG; Beets GL
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27509881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
    Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
    Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer.
    Lee SY; Kim CH; Kim YJ; Kim HR
    Oncology; 2015; 89(6):311-8. PubMed ID: 26426305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.